Item type |
デフォルトアイテムタイプ(フル)(1) |
公開日 |
2007-12-10 |
タイトル |
|
|
タイトル |
Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway |
|
言語 |
en |
作成者 |
Ishikawa, Chie
Matsuda, Takehiro
Okudaira, Taeko
Tomita, Mariko
Kawakami, Hirochika
Tanaka, Yuetsu
Masuda, Masato
Ohshiro, Kazuiku
Ohta, Takao
Mori, Naoki
|
アクセス権 |
|
|
アクセス権 |
open access |
|
アクセス権URI |
http://purl.org/coar/access_right/c_abf2 |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
bisphosphonate |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
incadronate |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
human T-cell leukaemia virus type I |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
adult T-cell leukaemia |
主題 |
|
|
言語 |
en |
|
主題Scheme |
Other |
|
主題 |
mevalonate |
内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
Anti-resorptive bisphosphonates are used for the treatment of hypercalcemia and bone complications associated with malignancies and osteoporosis, but have also been shown to have anti-tumour effects in various cancers. Adult T-cell leukaemia (ATL) is a fatal T-cell malignancy caused by infection with human T-cell leukaemia virus type I (HTLV-I), and remains incurable. ATL is associated with osteolytic bone lesions and hypercalcemia, which are major factors in the morbidity of ATL. Thus, the search for anti-ATL agents that have both anti-tumour and anti-resorptive activity is warranted. The bisphosphonate agent, incadronate prevented cell growth of HTLV-I-infected T-cell lines and primary ATL cells, but not of non-infected T-cell lines or normal peripheral blood mononuclear cells. Incadronate induced S-phase cell cycle arrest and apoptosis in HTLV-I-infected T-cell lines, and treatment of these cells with substrates of the mevalonate pathway blocked the incadronate-mediated growth suppression. Incadronate also prevented the prenylation of Rap1A protein. These results demonstrated that incadronate-induced growth suppression occurs by interfering with the mevalonate pathway. Importantly, treatment with incadronate reduced tumour formation from an HTLV-I-infected T-cell line, when these cells were inoculated subcutaneously into severe combined immunodeficient mice. These findings suggest that incadronate could be potentially useful for the treatment of ATL. |
内容記述 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
論文 |
出版者 |
|
|
言語 |
en |
|
出版者 |
Blackwell Publishing |
言語 |
|
|
言語 |
eng |
資源タイプ |
|
|
資源タイプ |
journal article |
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
識別子 |
|
|
識別子 |
http://hdl.handle.net/20.500.12000/2608 |
|
識別子タイプ |
HDL |
関連情報 |
|
|
|
識別子タイプ |
URI |
|
|
関連識別子 |
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2141.2006.06445.x |
関連情報 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1111/j.1365-2141.2006.06445.x |
収録物識別子 |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
0007-1048 |
収録物識別子 |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA00574570 |
収録物名 |
|
|
言語 |
en |
|
収録物名 |
British journal of haematology |
書誌情報 |
巻 136,
号 3,
p. 424-432
|